Last reviewed · How we verify
X842
X842 is a small molecule that targets the SGLT2 receptor.
X842 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | X842 |
|---|---|
| Also known as | Undecided, X842 capsules |
| Sponsor | Jiangsu Sinorda Biomedicine Co., Ltd |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
By inhibiting SGLT2, X842 reduces glucose reabsorption in the kidneys, leading to decreased blood glucose levels. This mechanism is particularly useful in the treatment of type 2 diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Increased risk of genital yeast infections
Key clinical trials
- Mass Balance Study of [14C]X842 in Healthy Adult Male Subjects (PHASE1)
- The Phase III Clinical Trial of X842 Capsules for Reflux Esophagitis (PHASE3)
- Study to Evaluate the Safety and Efficacy of X842 in Patients With Reflux Esophagitis (PHASE2)
- Relative Bioavailability of Linaprazan for the Test Formulation vs. Reference Formulation (PHASE1)
- A Study to Investigate the Pharmacokinetics and ECG Effects of Linaprazan Glurate (PHASE1)
- A Study in Patients With Erosive Esophagitis to Investigate Safety, Tolerability, and Healing Rates After 4 Weeks Treatment of X842 or Lansoprazole and Symptom Pattern During Subsequent 4 Weeks Treatment With Lansoprazole (PHASE2)
- Single-dose and Multiple-dose X842 Phase 1 Study (PHASE1)
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of X842 in Human: A Single/Multiple Ascending Dose Study (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- X842 CI brief — competitive landscape report
- X842 updates RSS · CI watch RSS
- Jiangsu Sinorda Biomedicine Co., Ltd portfolio CI